INTRODUCTION
Glycolysis is the metabolic pathway that converts glucose to pyruvate. The free energy released in this process is utilized to form the high-energy compounds ATP and NADH. A high rate of glycolytic flux, even in the presence of oxygen, is a central metabolic hallmark of tumors. This phenomenon is historically known as the 'Warburg Effect'. 1 The rate of glycolytic flux is controlled at different levels and by different mechanisms. One of the critical modulators is the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6P2) by 6-phosphofructo-1-kinase (PFK-1), which is the first committed rate-limiting step of glycolysis. 2 The intracellular allosteric regulator fructose 2,6-bisphosphate (F2,6P2) is a potent activator of PFK-1.
3 F2,6P2 increases the affinity of PFK-1 for F6P and overrides the tonic allosteric inhibition of PFK-1 by ATP, allowing glycolytic flux through the PFK-1 checkpoint and into F1,6P2 synthesis. 3 The intracellular steady-state concentration of F2,6P2 is controlled by a family of homodimeric and bifunctional enzyme PFK-2/FBPase (PFKFB). 4, 5 Despite the high sequence homology (85%) of their core catalytic domains, the four isozymes of PFKFB (PFKFB1-4) display distinct properties, including tissue expression profiles, the ratio of their kinase/phosphatase activities, and their response to protein kinases, hormonal and growth factor signals. 6, 7 The bifunctional isoenzyme encoded by the pfkfb3 gene has the highest kinase: phosphatase activity ratio, which in turn sustains high glycolytic rates. 8 Furthermore, PFKFB3 exists different spilce variants. For example, six splice variants of PFKFB3 have been found in the human brain. 9 Confirming the activity and localization of these splice variants may help improve our understanding of the regulation of PFKFB3 and its function in tumor cell glycolysis, as well as its requirement for tumor growth.
The pfkfb3 gene is localized on chromosome 10p15.1 (ref. 10 ) and contains multiple copies of the oncogene-like AUUUA instability element in its 3ʹ untranslated region (3′UTR) (Figure 1a) . 11 The pfkfb3 gene contains at least 19 exons, and alternative splicing of the COOH-terminal variable region leads to the expression of at least six structural isoforms, termed UBI2K1-6 in humans 9 ( Table 1 ). The PFKFB3 protein consists of two homodimers. The monomer structure is divided into two functional domains within the same polypeptide chain. 4, 7, 12 The C-terminal domain contains the bisphosphatase activity of the enzyme. [13] [14] [15] This domain catalyzes the hydrolytic degradation of F2,6P2 into F6P and inorganic phosphate (Pi) . The N-terminal domain is responsible for the synthesis of F2,6P2 from F6P and ATP ( Figure 1b) . 14, 16, 17 The PFKFB3 protein is ubiquitously expressed, with especially high levels in proliferating tissues, transformed cells, solid tumors and leukemia cells.
18 PFKFB3 expression could be upregulated in response to mitogenic, inflammatory and hypoxia stimuli and during the DNA synthesis phase of the cell cycle. 18 Considering its significance in cancer metabolism, further explanation of the function of PFKFB3 in diverse cancers is necessary.
REGULATORY MECHANISMS OF PFKFB3
The oncogenic Ras signaling pathway has been invoked as a central regulator of the glucose metabolism of cancer via the activity of PFKFB3. 19, 20 Ras inhibition in glioblastoma downregulates hypoxia-inducible factor-1 alpha (HIF-1α), reducing the expression of the pfkfb3 gene and causing glycolysis shutdown and cell death. 21 Constitutive HER2 expression increases PFKFB3 expression and glucose metabolism in breast cancer cells. 22 Loss of p53 and PTEN and/or other tumor suppressor functions also stimulates glycolysis in part by activating the regulatory bifunctional PFKFB3 family. 23, 24 In addition, the transcriptional corepressor myeloid translocation gene 16 (MTG16) could act as a brake on glycolysis, stimulating mitochondrial respiration and inhibiting cell proliferation through suppression of PFKFB3-4. 25 Different stimuli have been reported to induce gene expression of pfkfb3. For example, hypoxia, 26 progestin 27 and estradiol 28 induce PFKFB3 expression through interactions of HIF-1, progesterone receptor (PR), and estrogen receptor (ER) with their own consensus response elements located at the pfkfb3 promoter. Circadian-driven transcription factor 'CLOCK' could also bind to pfkfb3 promoter at 'E-box' site to increase the transcription of pfkfb3 in cancer cells. PFKFB3 inhibition significantly retarded the growth of implanted human tongue cancer cell in mice only at certain time points within the circadian cycle. This finding indicates the significance of time-based PFKFB3 inhibition in cancer treatment. 29 Growth factors, such as insulin, 30 proinflammatory molecules such as interleukin 6 (IL-6), 31 lipopolysaccharide (LPS) and adenosine 32 or different stress stimuli (NaCl, H 2 O 2 , UV radiation or anisomycin) 33 , increase pfkfb3 gene expression levels. The major signal pathways involved in PFKFB3 regulation are shown in Figure 2 .
The mRNAs of all PFKFB3 isoforms contain multiple copies of the AUUUA instability motif in their 3′UTR AU-rich elements. 34, 35 It was reported recently that miR-206 and miR-26b directly interact with the 3′UTR of PFKFB3 mRNA, resulting in attenuation of glycolysis in breast cancer and osteosarcoma, respectively. 36, 37 Other miRNAs, including hsa-miR-26b-5p and hsa-miR-330-3p, are also expected to have binding sites in the 3′UTR of PFKFB3, although functional validation remains to be performed. 37 The PFKFB3 isoenzyme is phosphorylated at a consensus site, Ser 461 , within the C-terminal region by mitogen-activated protein kinaseactivated protein kinase 2 (MK2), 33 AMP-activated protein kinase (AMPK), 38 protein kinase A (PKA) and protein kinase C (PKC), 39 thus making it responsive to multiple external signals. Sglutathionylation 40 and demethylation 41 of PFKFB3 induced by high reactive oxygen species (ROS) in cancer cells cause a shift of glucose utilization from glycolysis toward the NADPH-producing pentose phosphate pathway (PPP), resulting in ROS detoxification. The PFKFB3 isoenzyme is degraded by the E3 ubiquitin ligase anaphase-promoting complex/cyclosome-cadherin1 (APC/CCdh1) via the KEN box. 42 A decrease in the activity of APC/CCdh1 in mid-to-late G1 phase leads to the accumulation of PFKFB3.
42 PFKFB3 is also a substrate for another ubiquitin ligase, SKP1-CUL1-F-box-protein (SCF), at the onset of S-phase via the DSG box, and thus the activity of PFKFB3 occurs in a short interval, coinciding with a peak in glycolysis in mid-to -late G1. 43 The findings led to the identification of the roles of these ubiquitin ligases in the metabolic regulation of the cell cycle and, consequently, cell proliferation. The degradation of PFKFB3 by those two enzymes induced by mitogenactivated protein kinase 14 (MAPK14) also leads to the reduction of ROS. 44 The detoxification of ROS related to PFKFB3 is presented in Supplementary Figure 1 . PFKFB3 is differentially regulated both at the transcriptional and post-transcriptional levels ( Table 2) .
ROLES OF PFKFB3 BEYOND GLYCOLYSIS
Although the glycolytic role of PFKFB3 in cancer progression has been the subject of numerous functional studies, some researchers have also focused on the functions of PFKFB3 beyond glycolysis. Recent observations have established that PFKFB3 is also trafficked to the nucleus in multiple cell lines via a highly conserved nuclear localization motif in the C-terminal domain, and ectopic expression of wild-type PFKFB3 in the nucleus stimulates cellular proliferation without an effect on glucose metabolism. 45 The product of PFKFB3, F2,6P2, activates cyclin-dependent kinases (Cdks) and then stimulates the Cdk-mediated phosphorylation of the Cip/Kip protein p27, which in turn results in decreased levels of p27 due to ubiquitination and proteasomal degradation by Cdk1. 45 As p27 is a potent suppressor of the G1/S transition and activator of apoptosis, the known requirement for PFKFB3 for cell cycle progression and prevention of apoptosis may be partly due to the ability of F2,6P2-induced p27 degradation. 46, 47 The effect of siRNA silencing of PFKFB3 is reversed by co-siRNA silencing of p27. 47 These results confirm that PFKFB3 expression may not only be essential for the regulation of glycolysis in the cytoplasm, but also in the control of the cell cycle in the nucleus and maintenance of an anti-apoptotic state.
ROLES OF PFKFB3 IN CANCER
Loiseau et al. 48 discovered that there was no bisphosphatase activity of PFKFB in hepatocellular carcinoma (HCC) cells, which was hypothesized as a key mechanism accounting for the loss of control of glycolysis. Although multiple PFKFB isoforms are almost certainly co-expressed in these tumor cells, the absence of bisphosphatase activity supports the explanation that the dominantly expressed PFKFB enzyme in these cells is PFKFB3. The PFKFB3 protein has two homodimeric subunits. Each subunit of PFKFB3 comprises two functional domains: an N-terminal kinase domain and a C-terminal phosphatase domain. The kinase activity catalyzes the production of F2,6P2 and ADP from F6P and ATP, which highly promote the glycolytic pathway. The phosphatase activity dephosphorylates F2,6P2 to produce F6P and Pi. Targeting PFKFB3 in cancer cells Enhanced glycolysis is important for cancer development. 51 As a key regulator of glycolysis, PFKFB3 plays an important part in oncogenesis and the survival and proliferation of cancer cells in the tumor microenvironment. The roles of PFKFB3 in different cancer cell lines and possible mechanisms are summarized in Table 3 . PFKFB3 has been studied in various cancer cells. Most studies have demonstrated that cancer cell growth, proliferation, migration and metastasis are promoted when PFKFB3 expression is increased or the PFKFB3 isoenzyme is phosphorylated. In addition, gene expression inhibition by siRNA in HeLa cells 47, 52 and colon carcinoma cells, 53 or by miRNA in breast cancer cells Roles of PFKFB3 in cancer L Shi et al and osteosarcoma cells 37, 54 decreases the growth, proliferation and migration of these cells. PFKFB3 inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and its derivation 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) have been shown to reduce glucose metabolism and exhibit potent antitumor activity in several human cancer xenograft models, including tongue carcinoma, gastric cancer and head and neck squamous cell carcinoma. 29, 55, 56 These studies further proved the proto-oncogenic role of PFKFB3. A recent in vitro study found that PFKFB3 is a key effector protein of transforming growth factor β1 (TGFβ1), which is an inducer of epithelial-mesenchymaltransition (EMT) in tumor cells, 57 further suggesting a role of PFKFB3 in the cancer invasion process. Most of the literature has reported that increased PFKFB3 promotes tumorigenesis and proliferation. However, experimental result in astrocytoma cells is inconsistent. Zscharnack et al. 58 found that the PFKFB3 splice variant UBI2K4 is downregulated in high-grade astrocytoma relative to low-grade astrocytomas and corresponding non-neoplastic brain tissue. Overexpression of UBI2K4 decreased cell viability and anchorage-independent growth of U87 cells. Consequently, further study is needed to elaborate the exact role of PFKFB3 in different cancer cells.
Under different stimuli, the mechanisms involved in PFKFB3 regulation in different cancer cell lines differ. Even under the same stimuli, cancer cells also display diverse regulatory mechanisms for PFKFB3. For instance, under progestin stimulation, dual mechanisms operate to ensure glycolysis in breast cancer cells (increased expression and increased phosphorylation of PFKFB3). 27 To protect cancer cells from harm from high ROS, HeLa cells and human leukemia U937 cells utilize two different modifications of PFKFB3 (Sglutathionylation and demethylation of PFKFB3). 40, 41 Desideri et al. 44 suggested that decreased PFKFB3 entails loss of autophagy in HeLa cells, leading to increased resistance to nutrient deprivation. The possible mechanism is that ROS, a mild activator of autophagy, is detoxified by decreased PFKFB3 by shifting glycolysis to PPP. However, another study reported an opposite outcome that the selective inhibition of PFKFB3 induces increased autophagy in HCT-116 colon adenocarcinoma cells as a survival mechanism. 53 Together, the roles of PFKFB3 on cancer cells are widely studied in cell lines and xenograft models. However, its functions and mechanisms are not exactly the same. A genetically engineered cancer in vivo model is still lacking for further investigation.
Targeting PFKFB3 in cancer stem cells (CSCs) CSCs are a subgroup of cells within a tumor that have the ability of (1) self-renewal and differentiation into multiple cell types when transplanted; 59 (2) initiating new tumors or responsible for the dissemination of metastases; 60 (3) resisting to anticancer drugs or radiations. 61, 62 Pacini et al. 63 suggest that the undifferentiated state of stem cells is characterized by a decrease in oxidative phosphorylation, a reduced level of intracellular ATP and a smaller production of ROS. CSCs from colon carcinoma, 64 osteosarcoma, 65 epithelial ovarian cancer 66, 67 and breast cancer 68 were proved to rely on the glycolysis pathway rather than oxidative phosphorylation (OXPHOS) for their energy needs. However, leukemia 69 and pancreatic adenocarcinoma 70 support OXPHOS as the primary energy source of CSCs. Even in the same type of tumor CSCs, the glucose metabolic patterns from different studies differ. 71, 72 Nevertheless, the peculiar metabolic characteristic of CSCs becomes a therapeutic and diagnostic opportunity in cancer research. CD44 + CD24 − breast cancer stem-like cells are enriched in tumor-initiating and chemotherapy-resistant cells. 73, 74 Pfkfb3 is Roles of PFKFB3 in cancer L Shi et al one of the genes in the CD44 + CD24 − cell gene signature that has been related to an enhanced risk of distant metastasis and poor clinical outcome in breast cancer patients. 86 ,87 CieslarPobuda et al. 88 revealed that breast CSCs can be distinguished from induced pluripotent stem cells (iPS) or surrounding breast cancer cells based on differences in PFKFB3 and PFK-1 expression. They found that PFKFB3 and PFK-1 expression are higher in CSCs than in iPS cells. When cultured under hypoxic conditions, iPS cells and cancer cells change the expression levels of PFKFB3 and PFK-1 similarly in CSCs, supposing that CSCs might enhance glycolysis due to hypoxia-mediated modulation of restriction point (R-point) markers such as PFK-1 and PFKFB3. The different expression levels of PFKFB3 and PFK-1 among CSC, iPS cells and non-stem cancer cells suggest improved prospects for the more precise detection of CSCs and for clinical applications of stem cellbased therapies.
Targeting PFKFB3 in endothelial cells (ECs)
The blood vessel lumen is lined by a monolayer of ECs including tip cells and stalk cells, and each performs specific functions. 89, 90 ECs are also glucose addicted and highly glycolytic even in the presence of ample oxygen. 91, 92 A few possible explanations are as follows: (1) glycolysis generates ATP more rapidly to meet energy needs for EC motility compared to oxidative metabolism, thus quickly restoring more oxygen supply to the perivascular tissue; (2) glycolysis side pathways produce macromolecules needed for biomass duplication during cell division, which may further contribute to rapid vascular sprouting; (3) ECs can still depend on glycolysis to sprout in the milieu with less oxygen and glucose because glucose diffuses further away from vessels than oxygen; (4) by primarily maintaining glycolysis metabolism, ECs minimize the production of ROS, protecting ECs from their hyperoxic stress microenvironment. 91, [93] [94] [95] Roles of PFKFB3 in cancer L Shi et al
Tumor angiogenesis, represents one of the central hallmarks of cancer, is the growth of new blood vessels which supply nutrients for tumor growth, expansion and progression. 96 High microvessel density in tumor specimen correlates metastasis, recurrence, poor prognosis in many malignancies. 97, 98 During angiogenesis, endothelial cells proliferate so that new capillary blood vessels can develop from preexisting microvessels to tolerate blood flow. Induction of PFKFB3 by vascular endothelial growth factor (VEGF) promotes angiogenesis and endothelial migration by regulating the tube formation of filopodia and lamellipodia and directional migration. Silencing of PFKFB3 in ECs reduces vascular sprouting by decreasing the migration of tip cells and proliferation of stalk cells. 89, 91, 99, 100 A few other mechanisms may also underlie this effect: (1) PFKFB3 compartmentalizes with F-actin in lamellipodia to create an assembly line of glycolysis, facilitating efficient and rapid local ATP production to fuel migration; 91 (2) the increase in lactate upon increased PFKFB3 stimulates angiogenesis via activation of HIF-1α and upregulation of VEGF receptor 2 (VEGFR2); 101 (3) PFKFB3 also control cell proliferation via glycolysis-independent Cdks activities in the nucleus. 45 In contrast to traditional anti-angiogenic therapy that aims to inhibit angiogenesis, an emerging paradigm is to normalize characteristically chaotic tumor vasculature in order to improve blood perfusion, which could decrease hypoxia and increase drug accessibility. The normalized vessels might also resist shedding of cancer cells from the primary tumor, potentially reducing tumor metastasis. 102, 103 A recent study found that inhibition of PFKFB3 in melanoma tumor endothelial cells (TECs) induces tumor vessel normalization, thus reducing cancer cell invasion, intravasation and dissemination, and contributing to increased response to chemotherapy. 104 This effect is probably achieved by reducing VEcadherin endocytosis and inflammation in ECs and making pericytes more quiescent and adhesive under reduced glycolysis. By decreasing NF-κB signaling, TECs also lower the expression of cancer cell adhesion molecules, which contributes to metastasis inhibition of cancer cells. 104 Thus, targeting EC metabolism through PFKFB3 might offer unprecedented opportunities for anti-angiogenic therapies and inhibition of tumor growth.
Targeting PFKFB3 in immune cells
The Warburg effect has also recently been associated with many immune cell activities. For example, resting or quiescent T cells will switch from OXPHOS to aerobic glycolysis to provide sufficient ATP and precursor molecules for proliferation and survival when encountering antigens. [105] [106] [107] Chang et al. 108 found that when activated T cells are provided with co-stimulation and growth factor stimulation but are blocked from engaging in glycolysis, their ability to produce interferon-γ (IFN-γ) is markedly compromised. IFN-γ is a cytokine contributing to the inhibition of the development of chemically or virus-induced tumors. 109 T-cell activation is associated with a rapid increase in intracellular PFKFB3. PFKFB3 may be the dominant PFKFB family member involved in TCR/CD28-induced F2,6P2 synthesis and glycolysis. Augmented aerobic glycolysis is also important for regulating the activation and function of dendritic cells (DC) and macrophages. 32, 114, 115 DC activation and maturation are induced by Toll-like receptors (TLRs) ligands, stimulating a profound metabolic transition to aerobic glycolysis. The phosphatidylinositol 3ʹ-kinase (PI3K)/Akt signaling pathway controls this metabolic switch. 116 Increased PFKFB3 expression could be essential in protecting the viability of macrophages to develop their long-term defense and reparative functions in the inflammatory microenvironment. The expression of the transcription factors HIF1α, C/EBPβ, and Sp1 is activated in macrophages treated with LPS. LPS also increases AMPK activity in macrophages, which increases PFKFB3 phosphorylation. 32 Because these immune cell experiments were all performed in vitro and the cancer microenvironment in vivo is completely different, more studies in vivo and in cancer models are needed to illustrate the function of glycolysis in immune cells within cancer.
Chronic inflammation is acknowledged as the cause of various human cancers. 117, 118 For example, patients with inflammatory bowel disease have an increased risk for colorectal cancer (CRC). 119, 120 The AUUUA instability element found in the mRNA of pfkfb3 is also found in several inflammatory cytokine mRNAs (for example, IL-1, IFN-γ and granulocyte/macrophage colonystimulating factor, GM-CSF). 34, 35, 121 The inflammatory cytokine IL-6 stimulates aerobic glycolysis and promotes cell proliferation and migration in CRC cells. Pfkfb3 was the gene most downregulated by an anti-IL-6 receptor antibody in colorectal adenoma tissues. 77 We therefore speculate that the tumor inflammatory environment could be alleviated through PFKFB3 inhibition.
THERAPEUTIC POTENTIAL OF PFKFB3 INHIBITORS IN THE TREATMENT OF CANCER
As knowledge of PFKFB3 in cancer metabolism accumulates, there has been an increased interest in the identification and development of PFKFB3 inhibitors. It is known that current standard chemotherapeutic and irradiation protocols mainly target rapidly dividing cells. The data from Liu et al. 122 suggest the efficacy of these treatments could be enhanced by inhibition of glycolysis aimed specifically at slower growing cancer cells.
3PO is a well-studied suppressor of the basal catalytic activity of the PFKFB3 isozyme. It decreases intracellular F2,6P2, thus suppressing glycolytic flux in transformed cells. 3PO functions through its binding to the sites that the PFKFB3 protein binds and functions. Consequently, binding competition between 3PO and F6P for the binding area is possible. 84 However, Lineweaver-Burk double-reciprocal plot analyses have shown that 3PO exhibits a complex mechanism in the inhibition of PFK-2 activity that is both competitive and uncompetitive. Introduction of 3PO to various cancer cells, such as breast cancer, 123 bladder carcinoma cancer 83 and hepatocellular carcinoma 84 induces cytotoxicity, apoptosis and growth inhibition. An advantage is that 3PO and its optimized derivatives do not affect serum glucose, red blood cell and white blood cell concentrations when administered daily in vivo.
110
PFK15, a potent derivation of 3PO, was recently demonstrated 55, 56 to (1) cause cell cycle arrest in G0/G1 phase by blocking the cyclin-CDKs/Rb/E2F signaling pathway; (2) induce apoptosis through mitochondria; (3) inhibit invasion by downregulating focal adhesion kinase (FAK) and upregulating E-cadherin. Additionally, compared with other PFKFB3 inhibitors, PFK15 displays potent and selective activity against PFKFB3 with low cytotoxicity. 55, 124 The improved apoptosis potency of PFK15 was greater than the metabolic changes it induced. 124 Another potent and selective inhibitor of PFKFB3, PFK-158, displays broad antitumor activity and immunomodulatory effects in multiple human and syngeneic preclinical models. [111] [112] [113] A phase I clinical trial demonstrated that PFK-158 was successfully completed in 125 1-(3-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PQP), 126 5, 6, 7, 8-tetrahydroxy-2-(4-hydroxyphenyl) chrome-4-one (N4A) and 7, 8-dihydroxy-3-(4-hydroxyphenyl) chromen-4-one (YN1). 127 The further identification of small-molecule inhibitors of PFKFB3 may provide a new avenue for the development of novel chemotherapeutic agents.
CONCLUSION AND PERSPECTIVES
Knowledge of the function of PFKFB3 in cancer has advanced considerably in the past several years. In this review, we summarized the function of PFKFB3 in tumor metabolism and elucidated the regulatory mechanisms of PFKFB3. Furthermore, the role of PFKFB3 in human tumor cells, CSCs, ECs and immune cells, was discussed in this review. PFKFB3 represents a promising target for tumor treatment. However, until now, no PFKFB3 inhibitors have been approved to treat patients with cancer. 3PO is a potent inhibitor of PFKFB3 but poor water solubility makes this compound clinically unavailable. Other potent and selective inhibitors of PFKFB3, such as PFK15 and PFK-158, are under clinical trials for treating late-stage cancer patients. Recently emerged nanotechnology-based drug delivery carriers [128] [129] [130] have the ability to formulate various hydrophobic anticancer agents including 3PO, 131 thereby showing the potentials to improve the anticancer efficacy when used in vivo. On the other hand, specifying resistance mechanisms triggered by targeted therapies would allow for the specific selection of drug combinations.
It was recently demonstrated that lactic acidosis arising as a result of tumor metabolism allows cancer cells to develop strong resistance to glucose deprivation-induced cell death. 132 The theory that changing the pH of the tumor microenvironment with bicarbonate has been successfully applied in clinical treatment for patients with HCC that is not amenable to surgery, 133 which provided new insights into treating tumors by targeting their metabolism and microenvironment. Reasonably, we believe combining PFKFB3 inhibitor with environmental cells inhibition, such as immune suppressors or angiogenesis inhibitors, would probably generate a better effect of tumor eradication. For example, the PFKFB3 inhibitor PFK-158 could improve the antitumor activity of the immune checkpoint inhibitor anti-CTLA4 in the B16 mouse model. 112 Furthermore, tumors could rely on other metabolic pathways for energy supply besides glycolysis. For example, increased cholesterol synthesis and steroidogenesis occur throughout prostate cancer carcinogenesis rather than the classic 'glycolytic switch' observed in the majority of other solid tumors. 134, 135 Increased fatty acid oxidation is sufficient for cell survival and to protect cells from glucose withdrawal-induced death in Akt-overexpressing glioblastoma. 136 A synergistic anti-neoplastic effect of anti-metabolism agents is anticipated when combined with chemotherapeutic drugs. How these drugs interact and produce optimal effects warrants further investigations.
